Abstract
Melanomas are the deadliest form of skin cancer and, despite the low incidence, they represent 80% of the deaths from this type of tumor. The development of specific inhibitors to the mutant form of the onco-protein BRAF has put melanoma among the tumors benefiting from this compound, following the tendency of treatments that exploit the principle of molecular targeted therapy. However, m…